These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38648637)

  • 21. Limited sampling strategies for tacrolimus exposure (AUC0-24) prediction after Prograf(®) and Advagraf(®) administration in children and adolescents with liver or kidney transplants.
    Almeida-Paulo GN; Lubomirov R; Alonso-Sanchez NL; Espinosa-Román L; Fernández Camblor C; Díaz C; Muñoz Bartola G; Carcas-Sansuán AJ
    Transpl Int; 2014 Sep; 27(9):939-48. PubMed ID: 24861353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Limited sampling strategy for estimating individual exposure of tacrolimus in pediatric kidney transplant patients.
    Zhao W; Fakhoury M; Baudouin V; Maisin A; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2011 Dec; 33(6):681-7. PubMed ID: 22011724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Flexible limited sampling model for monitoring tacrolimus in stable patients having undergone liver transplantation with samples 4 to 6 hours after dosing is superior to trough concentration.
    Langers P; Press RR; den Hartigh J; Cremers SC; Baranski AG; Lamers CB; Hommes DW; van Hoek B
    Ther Drug Monit; 2008 Aug; 30(4):456-61. PubMed ID: 18641539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinically significant drug-drug interaction between tacrolimus and phenobarbital: the price we pay.
    Siddiqi N; Marfo K
    J Pharm Pract; 2010 Dec; 23(6):585-9. PubMed ID: 21507867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients.
    Braun F; Schütz E; Peters B; Talaulicar R; Grupp C; Undre N; Schäfer A; Armstrong VW; Oellerich M; Ringe B
    Transplant Proc; 2001 May; 33(3):2127-8. PubMed ID: 11377473
    [No Abstract]   [Full Text] [Related]  

  • 26. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients.
    Kagaya H; Miura M; Satoh S; Inoue K; Saito M; Inoue T; Habuchi T; Suzuki T
    J Clin Pharm Ther; 2008 Apr; 33(2):193-201. PubMed ID: 18315786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients.
    Velickovic-Radovanovic R; Mikov M; Catic-Djordjevic A; Stefanovic N; Mitic B; Paunovic G; Cvetkovic T
    Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):95-102. PubMed ID: 24596067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of Limited Sampling Strategies for the Estimation of Tacrolimus Area Under the Curve in Adult Kidney Transplant Recipients According to the Posttransplantation Time.
    Aouam K; Chadli Z; Hammouda M; Fredj NB; Aloui S; May ME; Boughattas N; Skhiri H; Chaabane A
    Ther Drug Monit; 2015 Aug; 37(4):524-30. PubMed ID: 25627405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus.
    Pawinski T; Luszczynska P; Durlik M; Majchrzak J; Baczkowska T; Chrzanowska M; Sobiak J; Glyda M; Kuriata-Kordek M; Kamińska D; Krajewska M; Klinger M
    Ther Drug Monit; 2013 Dec; 35(6):760-9. PubMed ID: 24192641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic interaction between tacrolimus and diltiazem: dose-response relationship in kidney and liver transplant recipients.
    Jones TE; Morris RG
    Clin Pharmacokinet; 2002; 41(5):381-8. PubMed ID: 12036394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a 2-Point Limited Sampling Strategy to Predict the Tacrolimus Area-Under-the-12-Hour-Curve in Kidney Transplant Recipients.
    Vadcharavivad S; Susomboon T; Kulabusaya B; Avihingsanon Y; Praditpornsilpa K; Townamchai N
    Ther Drug Monit; 2016 Oct; 38(5):614-20. PubMed ID: 27328329
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients.
    Chen YH; Zheng KL; Chen LZ; Dai YP; Fei JG; Qiu J; Li J
    Transplant Proc; 2005 Dec; 37(10):4246-50. PubMed ID: 16387090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data.
    van Duijnhoven E; Christiaans M; Schäfer A; Undre N; van Hooff J
    Transplant Proc; 1998 Jun; 30(4):1266-7. PubMed ID: 9636514
    [No Abstract]   [Full Text] [Related]  

  • 34. Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation.
    Monchaud C; de Winter BC; Knoop C; Estenne M; Reynaud-Gaubert M; Pison C; Stern M; Kessler R; Guillemain R; Marquet P; Rousseau A
    Clin Pharmacokinet; 2012 Mar; 51(3):175-86. PubMed ID: 22339449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling.
    Gustavsen MT; Midtvedt K; Vethe NT; Robertsen I; Bergan S; Åsberg A
    Ther Drug Monit; 2020 Jun; 42(3):407-414. PubMed ID: 31479042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group.
    Undre NA; Schäfer A
    Transplant Proc; 1998 Jun; 30(4):1261-3. PubMed ID: 9636512
    [No Abstract]   [Full Text] [Related]  

  • 38. Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy.
    Mendonza AE; Zahir H; Gohh RY; Akhlaghi F
    Ther Drug Monit; 2007 Aug; 29(4):391-8. PubMed ID: 17667791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling of Tacrolimus Exposure in Kidney Transplant According to Posttransplant Time Based on Routine Trough Concentration Data.
    Ben Fredj N; Woillard JB; Debord J; Chaabane A; Boughattas N; Marquet P; Saint-Marcoux F; Aouam K
    Exp Clin Transplant; 2016 Aug; 14(4):394-400. PubMed ID: 27506258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical influencing factors for daily dose, trough level, and relative clearance of tacrolimus in renal transplant recipients.
    Hu RH; Lee PH; Tsai MK
    Transplant Proc; 2000 Nov; 32(7):1689-92. PubMed ID: 11119894
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.